Brokerages Expect Cardiff Oncology, Inc. (NASDAQ:CRDF) Will Post Quarterly Sales of $80,000.00

Wall Street analysts forecast that Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Rating) will report $80,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Cardiff Oncology’s earnings. The highest sales estimate is $100,000.00 and the lowest is $50,000.00. Cardiff Oncology reported sales of $70,000.00 during the […]

Related Keywords

California , United States , Piper Sandler , Robertw Baird , Cardiff Oncology Inc , Life Insurance Co , Zacks Investment Research , Topco Ltd , Citigroup Inc , Nasdaq , Invesco Ltd , Wall Street , Cardiff Oncology , Get Rating , Zacks Investment , Investment Research , Polo Like Kinase , Nasdaq Crdf , Acrdf , Medical , Ratings , Consensus ,